Thermo Fisher Scientific Inc. (NYSE:TMO) has been recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2025. Despite experiencing a 21% decline in its stock value since the beginning of the year, the company remains a strong player in the long-term growth market. Thermo Fisher’s success is attributed to its large scale, diverse operations, and high-margin recurring revenue streams, which account for 83% of its total sales. The company specializes in providing instruments, diagnostics, bioproduction tools, and outsourced clinical and manufacturing services.
In the first quarter of 2025, Thermo Fisher Scientific reported a revenue of $10.36 billion, marking a 1% increase from the previous year. The company exceeded analysts’ expectations by $130 million, thanks to its focus on operational efficiency through the PPI Business System. Additionally, Thermo Fisher introduced several innovative products during the quarter to support its growth strategy.
As a solid dividend payer, Thermo Fisher Scientific boasts a robust cash position. In the latest quarter, the company generated an operating cash flow of $723 million and a free cash flow of $373 million. Furthermore, Thermo Fisher raised its dividend for the eighth consecutive year, offering a quarterly dividend of $0.43 per share and a dividend yield of 0.42% as of July 17.
While Thermo Fisher Scientific presents a promising investment opportunity, some AI stocks may offer greater potential returns with lower risks. For investors seeking undervalued AI stocks with significant upside potential, a free report on the best short-term AI stock is available.
In conclusion, Thermo Fisher Scientific Inc. continues to demonstrate resilience and growth in the pharmaceutical industry. With a focus on innovation, operational efficiency, and a solid dividend payout, the company remains a top contender in the market.
For more investment opportunities, check out the 13 Best Industrial Dividend Stocks to Buy Right Now and the 10 Best Passive Income Stocks to Buy Now.
Disclosure: None.
